DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety and Efficacy of Bimatoprost/Timolol (GanfortĀ®) Ophthalmic Solution in Korea

Information source: Allergan
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Glaucoma, Open-Angle; Ocular Hypertension

Intervention: bimatoprost/timolol (Drug)

Phase: N/A

Status: Completed

Sponsored by: Allergan

Official(s) and/or principal investigator(s):
Medical Director, Study Director, Affiliation: Allergan

Summary

This study is a Post-Marketing Surveillance study to evaluate the safety and efficacy of bimatoprost/timolol (Ganfort®) Ophthalmic Solution to treat open-angle glaucoma or ocular hypertension in Korea.

Clinical Details

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Number of Participants With Adverse Events and Adverse Drug Reactions

Secondary outcome: Change From Baseline in Intraocular Pressure (IOP)

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients treated with GanfortĀ® for open-angle glaucoma or ocular hypertension in

clinical practice. Exclusion Criteria:

- None.

Locations and Contacts

Seoul, Korea, Republic of
Additional Information

Starting date: August 2009
Last updated: June 22, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017